Sector News

Gilead cuts ribbon on innovative new laboratory, announces additional $100m investment in Edmonton

May 29, 2015
Life sciences
/CNW/ – Today, Gilead Alberta ULC, a wholly-owned subsidiary of Gilead Sciences, Inc. (Nasdaq: GILD), officially opened the first of two new laboratory buildings at its Edmonton campus, and announced an additional $100 million investment to further expand and upgrade the site as the biopharmaceutical company broadens its pipeline of treatments in areas of unmet medical need.
 
“We are pleased to continue our growth here in Alberta, as evidenced by the significant investment and expansion announced today,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “Our facility in Edmonton is home to many leading scientists and researchers who are working to improve patient care around the world.”
 
Gilead Alberta’s two new laboratory buildings, including the one that opens today, will allow for close to 170 additional highly trained scientists in Edmonton and enable Gilead Alberta to expand to support the development and manufacturing of investigational drugs, supply active pharmaceutical ingredients (API) for clinical research programs and contribute to new product launch supplies in the areas of hepatitis C virus (HCV), HIV/AIDS and oncology. A second laboratory building is under construction and set for completion in the spring of 2016.
 
The additional $100 million investment at the campus will include the construction of a new process tower for the additional manufacturing of API, a maintenance facility, and upgrades to the existing site. The process tower will expand the capabilities of the operations in Edmonton to allow for the handling of more potent compounds.
 
Edmonton is home to Gilead’s largest operation in Canada, with more than 300 employees. In 2014, Gilead invested more than $100 million in research and development in Canada, almost half of that in Alberta. “Made in Canada” solutions include the Edmonton facility providing significant clinical trial quantities for Gilead’s global research, clinical trial supplies for HCV and HIV  therapies and material for oncology research.
 
“The state-of-the-art research and development facility that opens today marks an important milestone for Gilead as it further increases its contribution to Alberta’s growing life-sciences industry,” said Dr. Robin Nicol, Vice President of Chemical Operations and General Manager, Gilead Alberta ULC. “As Gilead expands into new therapeutic areas, the additional laboratory space enables our process and analytical chemistry teams in Edmonton to make an even greater contribution to the development of life-saving therapies for patients.”
 
In Alberta, Gilead initiatives support the province’s advanced education system and not-for-profit sector such as the Northern Alberta Institute of Technology’s (NAIT) Chemical Technology program, the Industrial Internship Program at the University of Alberta and the Centennial Centre for Interdisciplinary Sciences at the University of Alberta. Gilead staff also support and volunteer with many local programs across Edmonton, including the CapitalCare Foundation and the annual AIDS Walk for Life.
 
Source: Gilead Sciences

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.